1·In patients receiving lenalidomide maintenance therapy, hematologic second primary malignancies occurred in 7.5% of patients compared to 3.3% in patients receiving placebo.
接受来那度胺维持治疗的患者中，有7.5%出现了血液第二原发性恶性肿瘤，而接受安慰剂的患者中有3.3%。
2·Lenalidomide is not technically a chemotherapy drug, is given orally and in certain situations can by very effective.
来那度胺，技术上来讲并非一种化疗药物，可以口服并且某些情况下非常见效。